// App-Quantinova.ai

: The Combination of Decitabine Plus Venetoclax Is an Active Salvage Therapy for AML Post HR-MDS Progressed during Treatment with Azacitidine Based Regimens

Researchers

Presenter

  • Angela Consagra

Principal Investigators

  • Alessandro Sanna

  • Marco Gabriele Raddi

  • Luca Rigodanza

  • Enrico Attardi

  • Cristina Amato

  • Margherita Cassari

  • Elena Tofacchi

  • Giorgio Mattiuz

  • Sven de Pourcq

  • Valeria Santini

Medical Centers

  • MDS Unit, Hematology, AOU Careggi, University of Florence, Florence, Italy

  • Department of Experimental and Clinical Medicine, MDS Unit, Hematology, AOU Careggi - University of Florence, Florence, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Hormone receptor

Drug/Treatment

  • Azacitidine

  • Vidaza

  • Decitabine

  • Venetoclax

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved